FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF V600E Mutation By Ogkologos - March 11, 2026 79 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the BREAKWATER study Source RELATED ARTICLESMORE FROM AUTHOR Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Tarlatamab Transdermal Oestradiol Patches Non-inferior to LHRH Agonists Regarding Metastasis-Free Survival in Patients with Locally Advanced Prostate Cancer MOST POPULAR How to Be Brave When Your Parent Has Cancer: A Kid’s... April 13, 2021 Time to meet our new chief scientist – Professor KJ Patel October 12, 2022 How longer waiting times are impacting teens and young adults April 27, 2023 Pruebas genéticas para el cáncer en familias: Preguntas y respuestas con... May 19, 2022 Load more HOT NEWS A Large Genomic Analysis Identifies That Persistent Tumour Mutational Burden Is... Intracranial Efficacy of Pembrolizumab in Patients with Brain Metastases Efficacy of Afamitresgene Autoleucel for HLA-A*02-positive and MAGE-A4-positive Synovial Sarcoma Following... Spotlight On: Exercise Physiologists in Cancer Care
